Goal is to stimulate new bone formation as opposed to preventing further loss.!--h2>
CardioVascular BioTherapeutics signed a sponsored research agreement with Tufts University School of Medicine to study the potential use of human fibroblast growth factor-1, the active component of Cardio Vascu-Grow™, to treat patients with osteoporosis.
Current marketed therapies for osteoporosis, including the bisphosphonates, such as Merck’s Fosamax, primarily act by inhibiting the breakdown of bone in osteoporosis but do not stimulate new bone formation, explains CardioVascular BioTherapeutics. The collaborators hope that research will lead to a bone growth factor to actually add back lost bone.
Michael Rosenblatt, M.D., professor of physiology and medicine at Tufts University School of Medicine, will conduct a six-month study in an animal model of osteoporosis to test human fibroblast growth factor-1 for its activity to reverse bone loss.